Literature DB >> 15194452

Role of endothelin ETB receptor in partial ablation-induced chronic renal failure in rats.

Yuka Okada1, Mariko Nakata, Hiromi Izumoto, Mai Takasu, Naoko Tazawa, Masanori Takaoka, Cheryl E Gariepy, Masashi Yanagisawa, Yasuo Matsumura.   

Abstract

We investigated the role of endothelin ET(B) receptor in the remnant kidney model of chronic renal failure, by using the spotting-lethal (sl) rat, which carries a naturally occurring deletion in the endothelin ET(B) receptor gene. After 5/6 nephrectomy, systolic blood pressure and renal functional parameters were measured for 12 weeks. At the end of the experimental period, arterial blood sample, remnant kidney, heart and aorta were collected and used for biochemical measurements and histopathological studies. The ET(B)-deficient sl/sl rats exhibited earlier and higher increases in systolic blood pressure, urinary protein excretion, blood urea nitrogen and plasma creatinine concentration, compared with cases in wild-type rats. Histopathologic examination of the kidney revealed glomerular and tubular lesions, alterations of which were more severe in sl/sl than in wild-type rats. While aortic endothelin-1 contents were increased similarly in both groups, the level of renal endothelin-1 content was significantly elevated in sl/sl rats, but not in the wild-type rats. These results suggest that enhanced endothelin-1 production is at least partly responsible for the increased susceptibility to partial ablation-induced chronic renal failure in ET(B) receptor-deficient rats and that ET(B) receptor-mediated actions are protective against vascular and renal injuries in this disease.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15194452     DOI: 10.1016/j.ejphar.2004.04.046

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  2 in total

1.  Angiotensin II receptor blocker irbesartan attenuates cardiac dysfunction induced by myocardial infarction in the presence of renal failure.

Authors:  Ryo Watanabe; Jun-Ichi Suzuki; Kouji Wakayama; Hidetoshi Kumagai; Yuichi Ikeda; Hiroshi Akazawa; Issei Komuro; Mitsuaki Isobe
Journal:  Hypertens Res       Date:  2015-12-10       Impact factor: 3.872

2.  Tauroursodeoxycholic acid (TUDCA) abolishes chronic high salt-induced renal injury and inflammation.

Authors:  Carmen De Miguel; Randee Sedaka; Malgorzata Kasztan; Jeremie M Lever; Michelle Sonnenberger; Andrew Abad; Chunhua Jin; Pamela K Carmines; David M Pollock; Jennifer S Pollock
Journal:  Acta Physiol (Oxf)       Date:  2018-12-23       Impact factor: 6.311

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.